Log in
Enquire now
‌

US Patent 7375213 Methods of producing C-aryl glucoside SGLT2 inhibitors

Patent 7375213 was granted and assigned to Bristol-Myers Squibb on May, 2008 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent

Patent attributes

Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7375213
Date of Patent
May 20, 2008
Patent Application Number
10745075
Date Filed
December 23, 2003
Patent Citations Received
‌
US Patent 12115179 Pharmaceutical composition, methods for treating and uses thereof
3
‌
US Patent 11666590 Pharmaceutical composition, methods for treating and uses thereof
4
‌
US Patent 11833166 Pharmaceutical composition, methods for treating and uses thereof
5
‌
US Patent 11918596 Pharmaceutical composition, methods for treating and uses thereof
6
‌
US Patent 11660308 Pharmaceutical composition comprising dapagliflozin
7
Patent Primary Examiner
‌
Shaojia Anna Jiang
Patent abstract

Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7375213 Methods of producing C-aryl glucoside SGLT2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.